From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Tom Winnifrith Bearcast: A sleazy PWC report does not excuse grotesque NED share option greed at Optibiotix, it stinks

By Tom Winnifrith | Saturday 8 January 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


I start with a few minutes on Woodlarks. This may be my last year doing the Rogue Bloggers Walk but myself, Lucian Miers, and Jonathan Price are minded to do it once more in May or June. On the basis that it could be a last hurrah and that you may want to consider a way of shifting that Christmas belly bulge how about you join us in 2022? Then onto Optibiotix (OPTI) where its NEDs have behaved in a most disgraceful way with free money share option troughing. As a loyal shareholder this is another kick in the gonads for me and I urge Steve O’Hara to sack three of the four of them and replace them with one new, less greedy, individual. Actually I’d go for all four booting out chairman Neil Davidson as well.

You must be a paid subscriber to listen to Bearcast
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 17:54:33